Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic gpNMB Expressing Triple Negative Breast Cancer”

2 trials

Showing 2 of 2 results

Not applicableNo Longer AvailableNCT03067935
What this trial is testing

Individual Patient Expanded Access-Glembatumumab Vedotin

Who this might be right for
Metastatic gpNMB Expressing Triple Negative Breast Cancer
Celldex Therapeutics
Testing effectiveness (Phase 2)Study completedNCT01997333
What this trial is testing

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Who this might be right for
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Celldex Therapeutics 327

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation